Aesthetic Medical Device Adverse Events and Recalls: A MAUDE Data Analysis

A data-driven analysis of FDA MAUDE adverse events and recalls across aesthetic device classes, analyzing breast implants, lasers, dermal fillers, and cryolipolysis systems.

Executive Summary: Mapping Post-Market Safety in Aesthetic Medicine

The market for aesthetic medical devices has experienced rapid growth, driven by increasing patient demand for both surgical and non-surgical procedures. According to statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), approximately 37.9 million aesthetic procedures were performed globally in 2024 (comprising 17.4 million surgical and 20.5 million non-surgical interventions), with the United States leading at approximately 6.1 million procedures.

With this high volume comes an increased responsibility for post-market safety monitoring. While manufacturers and practitioners focus on clinical efficacy and patient satisfaction, regulatory affairs and quality assurance teams must monitor adverse events and recalls. (For the premarket side of this market — who holds the FDA clearances and PMAs — see our aesthetic device market structure analysis; this article covers the post-market safety burden for the same device classes.)

To map the safety landscape of aesthetic devices, we conducted a product-code-joined analysis of the FDA's Manufacturer and User Facility Device Experience (MAUDE) database and FDA recall registries. Isolating a specific dictionary of 50 aesthetic device product codes, the data reveals where safety risks concentrate, the impact of high-profile regulatory actions, and the primary root causes of recalls in this sector.

Direct Decision Brief

For manufacturers, clinical providers, and safety officers, this data-driven analysis yields four critical safety takeaways:

Severe Imbalance in Reporting: Aesthetic device adverse-event reports are overwhelmingly dominated by breast implants. Silicone gel and saline breast implants account for over 80 percent of all aesthetic device reports in the MAUDE summary.
The Impact of Recall Scrutiny: Adverse-event reporting volume is not static; it is highly reactive to regulatory actions and media attention. The July 24, 2019 Allergan BIOCELL textured breast implant recall triggered a massive, sustained surge in reporting that remains elevated.
Non-Implant Risk Profiles: While implants drive reporting volume, non-surgical devices present distinct safety profiles. Dermal fillers (LMH) primarily drive reports of localized tissue injuries, while cryolipolysis systems (OOK) show concentrated reports of Paradoxical Adipose Hyperplasia (PAH).
Recall Dynamics: Recall risk is concentrated in energy-based devices. Out of 304 aesthetic recalls analyzed, powered lasers (GEX) account for approximately 65 percent, with process control and reprocessing controls representing the leading root causes.

What the MAUDE Aesthetic Data Shows: Overall Volume and Severity

The compiled aesthetic device dataset captures 432,301 adverse-event report rows (representing 423,768 unique patient events) across 50 verified product codes.

An evaluation of these reports by severity and type reveals that the vast majority are classified as patient injuries rather than simple device malfunctions:

Injury: 380,324 reports (approximately 88.0 percent of the total dataset)
Malfunction: 43,699 reports (approximately 10.1 percent)
Other / Unspecified: 5,128 reports (approximately 1.2 percent)
Death: 388 reports (approximately 0.09 percent)
Missing / No Answer: 2,762 reports (approximately 0.6 percent)

The Dominance of Patient Injuries

In the broader FDA MAUDE database across all medical device categories, device malfunctions typically represent the largest share of submissions. However, in the aesthetic device sector, this ratio is reversed, with injuries constituting 88 percent of all reports.

This high proportion of injury reports is primarily driven by two factors:

Implant Integrity: Complications such as breast implant rupture, capsular contracture, and breast pain are clinically classified as patient injuries rather than simple device malfunctions.
Clinical Presentation: In non-surgical procedures (such as lasers or dermal fillers), a device failure (e.g., an energy spike or misdirected injection) is rarely reported as a malfunction unless it results in a visible patient injury, such as a burn, scar, or nodule.

Distribution by Product Code: Where the Reports Concentrate

Isolating the data by FDA product code reveals that post-market safety reports are highly concentrated in a small number of device categories. The top six product codes represent over 99 percent of all reports in the database:

Product Code	Device Class Description	Premarket Pathway	Total MAUDE Reports	Primary Event Type
FTR	Silicone Gel Breast Implant	PMA	229,485	Injury (223,988)
FWM	Saline-Filled Breast Implant	PMA	118,133	Injury (112,112)
GEX	Powered Laser Surgical Instrument	510(k)	43,687	Malfunction (34,052)
LMH	Dermal Filler (Polymer/Gel)	PMA	22,242	Injury (18,514)
OOK	Dermal Cooling / Cryolipolysis System	510(k)	11,285	Injury (11,077)
LCJ	Breast Tissue Expander	510(k)	5,207	Injury (4,298)

The Implant Concentration

Silicone gel breast implants (product code FTR, 229,485 reports) and saline-filled breast implants (product code FWM, 118,133 reports) together account for 347,618 reports, representing 80.4 percent of the entire aesthetic safety database. When tissue expanders (LCJ, 5,207 reports) are included, breast surgery devices constitute 81.6 percent of the post-market safety reporting burden.

This concentration reflects both the high volume of breast procedures performed historically and the intensive regulatory and legal scrutiny surrounding these devices over the past decade.

Reading This Number Alongside the Dedicated Breast-Implant Analysis

The 347,618 figure above is a strict product-code count — it sums every MAUDE row tagged to the FTR or FWM product code. Because many breast-implant reports are filed under brand or generic names rather than a product code, a broader text-matched count is substantially higher. Our dedicated FDA breast implant recall and BIA-ALCL MAUDE record analysis counts roughly 580,000 breast-implant MAUDE reports across 2015–2026 using brand and generic-name matching, breaks out the 1,380-case BIA-ALCL evidence base, and maps the 16 Class I recalls. This article uses the product-code lens deliberately, because it is the only way to compare breast implants apples-to-apples against the non-implant aesthetic classes (lasers, fillers, cryolipolysis) in the same table. The two numbers are consistent — they answer different questions, and both are reproduced from public FDA data.

The 2019 Allergan Recall Spike and Annual Reporting Trends

Analyzing the annual volume of adverse-event reports received by the FDA reveals a dramatic inflection point. The chart below shows the number of reports received per calendar year from 2015 through 2025:

Year	Total Aesthetic Device Reports	Breast Implant Reports (FTR + FWM)	Non-Implant Reports (Lasers, Fillers, OOK)
2015	3,476	363	3,113
2016	4,087	633	3,454
2017	10,465	5,700	4,765
2018	22,364	16,356	6,008
2019 (Recall Year)	43,761	38,949	4,812
2020	43,124	39,001	4,123
2021	42,171	35,523	6,648
2022	51,933	45,597	6,336
2023	50,787	40,809	9,978
2024	45,819	40,255	5,564
2025	46,584	40,245	6,339

The Textured Implant Recall Context

The data shows a massive, sudden surge in reports beginning in 2017 and peaking in 2019. Reports rose from 4,087 in 2016 to 43,761 in 2019—a tenfold increase in annual reporting volume.

This surge directly tracks the regulatory actions surrounding Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare type of T-cell non-Hodgkin lymphoma that can develop in the scar tissue capsule surrounding textured breast implants.

July 24, 2019 Regulatory Action: The FDA requested that Allergan voluntarily recall its BIOCELL textured breast implants and tissue expanders from the US market. The FDA determined that a recall was necessary to protect patient safety after reviewing updated global data.
The BIA-ALCL Case Counts: At the time of the recall request (July 24, 2019), the FDA's analysis of global data identified 573 unique BIA-ALCL cases and 33 deaths worldwide, with 481 of the cases attributed to Allergan BIOCELL implants. In a subsequent update on January 5, 2020, the case count rose to 733 cases and 36 deaths worldwide. As of the FDA's most recent published update (June 30, 2024), the tally had grown to 1,380 unique BIA-ALCL cases and 64 deaths, with roughly 86 percent associated with Allergan textured implants — the continued accumulation that keeps breast-implant reporting elevated.
Reporting Dynamics: The recall triggered extensive media coverage, patient notifications, and litigation. This prompted thousands of patients and providers to file retrospective MAUDE reports for historical complications, explaining why the reporting volume rose from a few hundred per year in 2015 to over 38,000 per year starting in 2019. The volume has remained at this elevated baseline (between 45,000 and 52,000 reports annually) through 2025.

Manufacturer Concentration

An audit of the manufacturers listed in the breast implant reports shows that the reporting burden is concentrated in two major suppliers:

Allergan (Costa Rica): 176,750 reports
Mentor Texas (including "Mentor" entries): 116,709 reports

Together, Allergan and Mentor account for approximately 84 percent of all breast implant-related safety reports, reflecting their historically dominant market share and the focus of textured implant safety actions.

Recall Profile: Aesthetic Device Recalls and Root Causes

While breast implants dominate adverse-event reporting, the distribution of product recalls follows a different pattern. An analysis of the 304 aesthetic device recalls in our registry database shows that energy-based systems—specifically powered lasers—represent the highest risk for product recalls. (For the all-device picture, see our broader FDA medical device recall root-cause trend analysis; this section isolates the aesthetic slice.)

Recalls by Product Code

Isolating the 304 recalls by product code reveals that lasers are responsible for the vast majority of actions:

pie title Distribution of 304 Aesthetic Device Recalls
    "Lasers (GEX)" : 199
    "Tissue Expanders (LCJ)" : 21
    "Lipoplasty (MUU)" : 15
    "Silicone Implants (FTR)" : 14
    "Saline Implants (FWM)" : 9
    "Dermal Fillers (LMH)" : 7
    "Other Product Codes" : 39

Lasers (GEX): 199 recalls (approximately 65.4 percent of all recalls)
Tissue Expanders (LCJ): 21 recalls
Lipoplasty / Liposuction Systems (MUU): 15 recalls
Silicone Gel Breast Implants (FTR): 14 recalls
Saline Breast Implants (FWM): 9 recalls
Dermal Fillers (LMH): 7 recalls
Dermal Cooling / Cryolipolysis (OOK): 6 recalls

Leading Recall Root Causes

An audit of the root cause descriptions recorded in the recall registry indicates that manufacturing process failures and design controls are the primary drivers of recalls:

Process Control (34 recalls): Failures in the manufacturing process that led to out-of-specification parts or contamination.
Reprocessing Controls (32 recalls): Inadequate validation of sterilization instructions or cleaning protocols for reusable handpieces and surgical guides.
Nonconforming Material/Component (23 recalls): Defective sub-assembly parts sourced from sub-tier suppliers that failed during operation.
Device Design (22 recalls): Latent design defects, such as software anomalies or electrical hazards, that required field modifications.
Error in Labeling (12 recalls): Inaccurate user manuals, missing contraindications, or incorrect dosage/energy setting instructions.
Radiation Control (11 recalls): Specific to lasers, failures to comply with federal laser safety standards (such as housing interlock failures or calibration drift).

Safety Profiles of Non-Implant Aesthetic Devices

Beyond breast surgery, the non-surgical aesthetic market relies heavily on dermal fillers, energy-based skin systems, and cryolipolysis (fat freezing). Each of these product classes presents a unique safety signature in the MAUDE database.

1. Dermal Fillers (Product Code LMH)

Dermal fillers (primarily hyaluronic acid, calcium hydroxylapatite, and poly-L-lactic acid formulations) account for 22,242 reports, with injuries representing 18,514 cases.

A review of the event descriptions shows that filler safety reports concentrate around:

Nodule and Granuloma Formation: Delayed-onset inflammatory nodules or hard lumps forming weeks or months after injection.
Infection: Bacterial contamination or biofilm formation at the injection site.
Vascular Occlusion (High Risk): The most critical complication, occurring when filler is accidentally injected directly into a blood vessel. This can lead to localized skin necrosis, scarring, or, in extremely rare cases of retrograde embolization, permanent blindness.
Manufacturer Concentration: Allergan (Pringy) / Allergan (manufacturers of the Juvederm line) represents 10,234 reports, Galderma / Q-Med (Restylane) represents 1,040 reports, and Merz (Radiesse/Belotero) represents 455 reports.

2. Cryolipolysis / Dermal Cooling (Product Code OOK)

Cryolipolysis systems (marketed primarily under the CoolSculpting brand by Allergan Pleasanton/Zeltiq) account for 11,285 reports, with injuries representing 11,077 cases.

The dominant safety story for cryolipolysis is Paradoxical Adipose Hyperplasia (PAH).

The Complication: PAH is a rare, delayed side effect where the targeted fat tissue in the treatment area responds to the extreme cold by expanding and hardening into a visible, painless mass rather than shrinking. This typically requires surgical liposuction or surgical excision to correct.
The Clinical Rate: Allergan Aesthetics has publicly disclosed that the clinical rate of PAH is approximately 1 in 3,000 treatments (roughly 0.033 percent), based on a commercial milestone of 17 million treatments performed.
The MAUDE Impact: In the MAUDE database, reports of PAH drove the OOK product code to the fifth-largest category in the dataset. Allergan Pleasanton / Zeltiq accounts for over 10,800 reports within this code.

3. Powered Lasers (Product Code GEX)

Lasers account for 43,687 reports, but unlike implants and fillers, the majority are classified as Malfunctions (34,052 reports) rather than injuries (8,775 reports).

Common laser malfunctions in the database include:

Laser Emission Failures: The laser failing to fire or firing continuously without user input due to software glitches or foot switch failures.
Calibration Drift: The actual output energy deviating from the selected clinical settings, leading to either insufficient efficacy or unintended thermal tissue damage.
Cooling System Malfunctions: Critical failures in the integrated cryogen sprays, sapphire contact cooling windows, or chilled air systems designed to protect the epidermis from thermal injury during laser firing.
Injuries: When laser injuries are reported, they are primarily superficial or deep epidermal burns, long-term post-inflammatory hyperpigmentation (PIH) or hypopigmentation, and permanent scarring.

Regulatory note: The FDA regulates powered lasers under Chapter V, Subchapter C of the Federal Food, Drug, and Cosmetic Act (Electronic Product Radiation Control). Laser systems must comply with performance standards in 21 CFR 1040.10, which mandate specific safety interlocks, optical path labels, and user controls to mitigate the risk of accidental exposure.

4. Breast Tissue Expanders (Product Code LCJ)

Tissue expanders are temporary implantable devices used to stretch skin and muscle to prepare for permanent reconstruction, typically following mastectomy. The dataset contains 5,207 reports for product code LCJ, with 4,298 injuries.

The primary post-market issues for tissue expanders concentrate around:

Magnetic Port Failures: Modern tissue expanders (such as the Allergan Natrelle 133 or Mentor Siltex expanders) often incorporate an internal magnetic port to guide clinicians during saline filling. These magnetic components pose a strict contraindication for Magnetic Resonance Imaging (MRI). If a patient undergoes an MRI, the magnetic field can dislodge or demagnetize the port, causing severe internal heating, skin burns, or device migration.
Leakage and Deflation: Tears in the silicone shell or failures of the fill valve leading to premature deflation and requiring surgical replacement.
Extrusion and Exposure: Skin flap necrosis leading to the device eroding through the tissue, exposing the shell, and necessitating immediate removal.

5. Lipoplasty / Liposuction Systems (Product Code MUU)

Lipoplasty systems—including mechanical, power-assisted, and ultrasonic-assisted liposuction devices—represent the primary surgical surgical tools in body contouring. The dataset includes 365 reports, with malfunctions representing the majority of entries.

Safety concerns for lipoplasty systems include:

Thermal Injury (Ultrasonic Devices): Ultrasonic-assisted liposuction systems utilize high-frequency acoustic energy to emulsify fat cells. If the probe contacts the skin flap or stays stationary for too long, it can cause severe internal and external thermal burns that are difficult to treat.
Canister and Tubing Failures: Malfunctions in the fluid suction path, vacuum regulators, or disposal canister seals during active surgery.
Clinical Complications: While rare in MAUDE (which captures device-related events, not general clinical risks), clinical complications include significant fluid shifts, hemorrhage, and lidocaine toxicity from tumescent solution.

Method and Limitations Note: Critical Data Hygiene

When analyzing and reporting medical device safety data, manufacturers, practitioners, and clinical researchers must maintain rigorous data hygiene and follow strict interpretation guidelines.

The Passive Surveillance Warning

The FDA's MAUDE database is a passive surveillance registry. This structure imposes three fundamental limitations that must be disclosed in any clinical or commercial analysis:

No Incidence or Prevalence: MAUDE reports represent absolute counts of submissions. Because the total number of devices sold or procedures performed (the denominator) is not recorded in the database, it is impossible to calculate the actual rate of occurrence or incidence of any complication from MAUDE data alone.
No Proof of Causality: The submission of an adverse-event report to the FDA does not constitute an admission or determination that the device caused the event. Reports may contain incomplete, inaccurate, or unverified clinical information.
Reporting Bias: Reporting volume is highly susceptible to external factors, including media attention, safety communications, litigation, and manufacturer reporting campaigns. A sudden increase in reports (such as the 2019 textured implant surge) reflects increased awareness and filing activity, not necessarily an increase in the biological rate of complications.

Product Code Limitations

A major methodological limitation when using FDA product codes is "code breadth." The FDA utilizes the GEX product code ("powered laser surgical instrument") to classify a wide range of devices.

While this code includes cosmetic and aesthetic lasers (such as those used for hair removal, skin resurfacing, and tattoo removal), it also includes surgical, urological, and ophthalmic lasers manufactured by firms like Boston Scientific and American Medical Systems (AMS).

Our database audit shows that:

American Medical Systems and Boston Scientific account for over 14,000 reports within the GEX category.
These reports are primarily related to urological laser fibers used in lithotripsy (kidney stone destruction) or prostate surgery.
Therefore, the 43,687 GEX laser reports are not entirely cosmetic. Any analysis that attributes the entire GEX category to aesthetic plastic surgery is inaccurate. Developers must disclose this code-breadth limitation.

Frequently Asked Questions (FAQ)

Why are breast implants so dominant in the aesthetic MAUDE data?

Breast implants are Class III devices subject to Premarket Approval (PMA) and intense regulatory surveillance. Complications like rupture or capsular contracture are well-defined clinical events. Furthermore, the 2019 Allergan BIOCELL recall and associated BIA-ALCL litigation triggered a massive public awareness campaign, prompting patients, doctors, and lawyers to file thousands of historical reports.

Does a high MAUDE report count mean a device is unsafe?

No. A high report count is primarily a reflection of high market penetration (number of devices sold), length of time on the market, and level of regulatory or public scrutiny. To determine a device's safety profile, the absolute report count must be compared against the total number of procedures performed to calculate a rate, and evaluated alongside controlled clinical trial data.

How do aesthetic device recalls compare with recalls across all medical devices?

Recalls across all medical devices are primarily driven by software defects, packaging failures, and sterility issues. In the aesthetic sector, recalls are heavily concentrated in energy-based systems (lasers) due to the complexity of electrical, software, and optical calibration systems. Implants and dermal fillers have very few recalls, but high adverse-event report counts due to long-term tissue interactions.

What is the difference between a device recall and a safety communication?

A device recall is an action taken by a manufacturer to address a specific product defect or compliance issue, which can involve removing the device from the market or correcting it in the field. A safety communication is an informational notice issued by the FDA or a manufacturer to alert clinicians and patients to an ongoing or newly identified risk (such as BIA-ALCL or dermal filler vascular occlusion) that does not necessarily require the product's removal but mandates updated clinical management.

How do aesthetic device adverse events differ from drug adverse events in FAERS?

Aesthetic device adverse events are reported to MAUDE (Manufacturer and User Facility Device Experience), which captures physical or mechanical complications associated with device components, implants, and energy delivery. Drug adverse events (such as reactions to botulinum toxins or lidocaine) are reported to FAERS (FDA Adverse Event Reporting System), which tracks physiological side effects and metabolic drug reactions — see our botulinum toxin adverse events FAERS analysis for the methodological counterpart to this article. Device reports are heavily centered on localized mechanical interactions and tissue reactions, while drug reports capture systemic and pharmacological events.

Sources

International Society of Aesthetic Plastic Surgery (ISAPS), "Global Survey on Aesthetic/Cosmetic Procedures Performed in 2024", Published June 19, 2025. Available at: ISAPS Global Survey 2024
U.S. Food and Drug Administration (FDA), "FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from Market", July 24, 2019. Available at: FDA Allergan Recall Announcement
U.S. Food and Drug Administration (FDA), "Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders", Safety Alert, July 24, 2019. Available at: FDA Allergan Safety Alert
American Cancer Society, "Breast Implant Recall: What You Need to Know", Patient Information. Available at: American Cancer Society Implant Recall Information
Allergan Aesthetics / AbbVie, "CoolSculpting FAQ - Paradoxical Hyperplasia Rates and Clinical Data", Corporate Media Disclosure. Available at: Allergan Aesthetics CoolSculpting Media FAQ
U.S. Food and Drug Administration (FDA), "MAUDE Adverse Event Report - CoolSculpting Elite System (Product Code OOK)", Database Record. Available at: FDA MAUDE OOK Record